ChemAxon provides chemical software solutions and applications for the biotechnology and pharmaceutical industries, which are successfully used in publishing, flavors and fragrances research, petroleum and fine chemicals development areas.

We bridge the gap between biology and chemistry with our web-enabled applications, the Biomolecule Toolkit and the BioEddie.

CCG (Chemical Computing Group) is a leading supplier of software solutions for life sciences. With a proven track record in scientific innovation, CCG continues to provide state-of-the-art applications in drug discovery to pharmaceutical, biotechnology and academic researchers. CCG’s software platform is the Molecular Operating Environment (MOE) which is used by computational chemists, medicinal chemists and biologists in the major pharmaceutical and biotechnology companies throughout the world. CCG has a very strong reputation for collaborative scientific support, maintaining support offices in both Europe and North America. Founded in 1994, CCG is headquartered in Montreal, Canada. For more information visit: www.chemcomp.com

C S Bio is a rapidly growing biotechnology company located on the northern edge of California’s Silicon Valley in Menlo Park, CA. C S Bio has grown to meet the increased demand for large quantities of cGMP produced peptides and Peptide APIs (Active Pharmaceutical Ingredients) which are produced at the Menlo Park production facility. As the world of biotechnology continues to utilize peptides more and more in the fields of therapeutics, vaccines, new drug discovery as well as bioengineering and nanotechnology, C S Bio is well positioned provide high quality clinical grade compounds to this rapidly growing industry. Our goal is to be able provide a seamless supply of peptide drugs and APIs to support the rapid growth of these programs. C S Bio has designed and built a state of the art large scale cGMP peptide manufacturing facility that can produce multi kilogram quantities for existing clients as well as new potential customers. C S Bio also features a complete line of automated peptide synthesizers with systems designed for R&D to large scale manufacturing systems of 500L and greater. These systems are validated for cGMP peptide drug production and can be found in peptide production laboratories and pharmaceutical companies worldwide.

Over the past several years C S Bio has cultivated relationships with several pharmaceutical companies that are poised take their peptide drugs to market in the near future. The company has taken several peptides from small scale R&D quantities to the point where we are now producing cGMP grade peptide in kilogram quantities. As the prospects of our client’s drug candidates grow, so does their need for larger batches of peptide for late stage clinical trials and eventually FDA approved peptide products on the market. C S Bio’s goal is to be able to meet and exceed those requirements and provide a seamless supply of peptide drugs to support the rapid growth of these programs. C S Bio has built a state of the art large scale cGMP peptide manufacturing facility that is capable of producing  multi kilogram quantities for these existing clients as well as new potential customers. No matter your peptide requirements, C S Bio will provide high quality service, compounds and equipment to ensure your peptide program's best chance for success.

DNASTAR has been developing innovative software to meet the needs of molecular biologists and structural biologists since 1984.  For the bulk of our history, we have supported life scientists performing traditional and next-generation DNA, RNA and protein sequence assembly, analysis and visualization.  We recently expanded our offering to include excellent products and pipelines supporting structural biology applications, including;

• Protein structure prediction
• Protein-protein docking
• Antibody, antigen and epitope binding predictions

At DNASTAR, we pride ourselves on our innovation.  We were at the forefront of molecular biology software when we started our company, we have been a leader in Next Generation Sequence (NGS) assembly and analysis software for the past decade, and we are now taking a leadership role in protein structure prediction, molecular docking software and related areas. The Lasergene Structural Biology Suite is based on best-in-class algorithms for protein structure prediction (I-TASSER) and docking (SwarmDock), as evidenced by objective competitions over many years.  We have incorporated these algorithms into easy to use workflows and powerful pipelines to help all biologists advance their protein research in silico. To complement the Lasergene Structural Biology Suite, DNSATAR also offers the Lasergene Genomics Suite, which provides everything needed for Next Generation Sequence assembly, alignment, and analysis in a single integrated package. We support all major NGS technologies and combined analysis with Sanger sequencing, making it easy to work with your data for any type of sequencing project.  DNASTAR’s proprietary NGS variant caller is the most accurate on the market, as validated using objective data and testing protocols. DNASTAR’s software is available on desktop computers, your in-house servers and on the Amazon cloud.  We want to ensure our software is available wherever and whenever you need it to accomplish your most important objectives. For each of the past 30 years, DNASTAR’s software has been cited in more peer reviewed publications than any other sequence analysis software package.  Scientists in more than 90 countries use DNASTAR software in their daily work and a broad range of organizations have adopted our software as their enterprise-wide DNA, RNA and protein sequence assembly and analysis solution. Free trial versions are available for all of our capabilities, as are a wealth of video tutorials and other support tools. Feel free to contact us at [email protected] to further discuss how to most effectively meet your research needs.

Market Leader in Label-Free Analysis Technologies

Pall ForteBio is a division of Pall Life Sciences that provides a complete solution of system, software, accessories, and reagents for label-free analysis.

Label-free interaction analysis is of increasing importance in the academic, pharmaceutical, and biotechnology markets. Detecting the formation and dissociation of molecular complexes enables the comprehensive characterization of biomolecular interactions and stability.

In contrast to traditional label-free systems, Octet and BLItz systems operate without the use of microfluidics, allowing for up to 6x higher throughput, reducing operating costs, and increasing system flexibility to accommodate a variety of sample types.

The information-rich data enable key insights into biological processes and molecular binding mechanisms. These technologies meet the needs of fields as diverse as biological research, biotherapeutic and small molecule drug development research, vaccine development and QC.

Customers using ForteBio’s label-free technology can draw confident conclusions about biomolecular interactions to facilitate development and process decisions.

Found in 1998, GL BIOCHEM is specializing in peptide reagents, generic peptide, custom peptide synthesis, custom antibody.  We offered peptide related products and services towards Pharmaceutical, Biotechnology and Life Sciences companies, and R&D institutes too. Our products are now well known in more than 30 countries. We have offices in major cities around the globe。With nearly 1,000 highly-trained staff and total 35,000 sqm. lab and production space , GL Biochem is now the largest manufacturer of research-grade peptides and peptide reagents globally.We applies the latest technology in our state-of-the-art production facilities to provide one-stop services for your needs and specifications.

Gyros Protein Technologies, enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications.  Our low to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab™xP workstation and GyrolabxPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.

Iris Biotech specializes in reagents for Drug Discovery, Drug Delivery, and Diagnostics. We have specific know-how and production capabilities to manufacture and supply products from the following areas:

1. Starting Materials for Peptide Synthesis, Peptidomimetics and Medicinal Chemistry
2. Technologies for Drug Delivery

Iris Biotech offers different linkers for the synthesis of Antibody-Drug-Conjugates (ADCs). Moreover, we provide the worldwide largest portfolio of PEGylating reagents, as well as a selection of certain poly(amino acids), which are biodegradable alternatives to PEG. Poly(glutamic acid) is a multivalent drug carrier system which is useful for diverse applications. Polysarcosine is a polypeptoid that shows excellent properties in terms of safety, synthetic control and versatility.

3. Reagents for Life Sciences and Diagnostics

This category includes enzyme substrates, inhibitors and inducers, metabolites, labeling reagents and cross-linkers, natural products with biological and pharmacological activity, carbohydrates, as well as dyes and fluorescent labels as tools for immunology, diagnostics, biochemistry and molecular biology.

4. Contract Manufacturing

We also provide Contract Manufacturing services in the above areas. Our strong points are, among other things, chiral small molecules (such as unnatural amino acids), complex heterocycles and monodisperse PEGs with various functional groups.

Our mission is to accompany our customers throughout their projects as a highly qualified supplier, all the way from R&D to production.

For more than 30 years, Lonza has been helping emerging and large biotech and pharmaceutical companies improve and advance their products. Whether for clinical or commercial supply, Lonza’s full set of development services, industry-leading manufacturing processes, global footprint, and broad chemical and biotechnology platforms enable you to optimize your time and costs throughout the pharmaceutical development process.

Lonza has the know-how and experience to handle almost any pharmaceutical or biotechnology challenge.  The company has industry leading experts specializing in active pharmaceutical ingredients (APIs), highly potent APIs, advanced intermediates, fine chemicals, antibody drug conjugates, peptides, vaccines, plasmid DNA, recombinant novel proteins, monoclonal antibodies, antibody fragments, cell-based therapeutics and viral-based therapeutics.

MaxCyte's flow electroporation is driving the next generation of cell-based medicines. Used in the discover, development, and manufacture of cell-based therapeutics, the MaxCyte GT® Flow Transfection System, MaxCyte STX® Scalable Transfection System, and MaxCyte VLX® Large Scale Transfection System enable the development of transfected cells for a range of applications.

Quinta-Analytica – Quality in Time

Quinta-Analytica is a a contract research organization whose primary task is to supply pharmaceutical companies with analytical service. Quinta-Analytica’s activity is mainly focused in studies and analyses required by regulatory authorities before a pharmaceutical company can introduce its new products to market.

Our company covers analytical service from research and development of methods to their application in both bioanalyses (bioequivalence, pharmacokinetics/toxicokinetics, clinical study monitoring) and pharmaceutical analyses (method validation, release testing, stability studies). This analytical service includes testing of large molecules of biopharmaceuticals.

Biopharmaceuticals represent a significant part of the pharmaceutical market. Quinta-Analytica offer comprehesive analytical testing of high-molecular weight pharmaceuticals, such as proteins and peptides, including analyses in GMP/GLP/GCP environment. We also test samples and evaluate  preclinical and/or clinical trials on biosimilars/biopharmaceuticals.

Unique specialties are testing of dry powder inhalation products, impurity structure elucidations combined with custom synthesis, reverse engineering, solutions for complaint batches and in-vitro clinical studies.

Quinta-Analytica has substantially enlarged its activities in clinical trials. It offers various clinical trials like bioavailability/bioequivalence and biodrug/biosimilars testing, safety and tolerability, PK/PD studies, dose-ranging and linearity. Quinta-Analytica has a team of experts with long-term experience in pharmacokinetic/bioequivalence studies of different design carried out for EU and USA.

Main advantage of Quinta-Analytica is the concentration of the analytical services at one place. Clinical unit with 60 beds, most-modern bioanalytical laboratory, laboratory for biopharmaceuticals, quality control lab, ICH stability chambers, analytical method development department and headquarters are located on one address. It enables to provide complete service (“turnkey contract”) or customized services in accordance to the sponsor’s requirements.

During the years from its foundation in 1997, it became the largest CRO in the Central and Eastern Europe. Focused, experienced and well-organized company, operating on the world market from the very beginning offers analytical expertise needed for your pharmaceutical projects. Its location in the middle of Europe (Prague, Czech Republic) gives a decisive advantage for pharmaceutical company logistics.

Quinta-Analytica is regularly inspected by national as well as international regulatory authorities. To date, Quinta-Analytica passed 10 GXP audits by U.S. Food and Drug Administration (FDA).